Phase II study of anastrozole in gynaecological cancers (Gynaecological Cancer InterGroup study)
The aim of this study is to assess the activity of anastrozole, in women with oestrogen-receptor- or progesterone-receptor-positive recurrent or metastatic gynaecological cancers. It includes selected patients with epithelial ovarian cancer, endometrial cancers, miscellaneous gynaecological sarcomas and granulosa and sex-cord stromal tumours of the ovary.
Cancer Australia, NCGC, AstraZeneca
Women with potentially hormone-responsive gynaecological cancers